Trial Profile

Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Nov 2024 According to a Johnson & Johnson media release, an overview of an ongoing Phase 3 FNAIT clinical study design will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10.
01 Oct 2024 Planned initiation date changed from 23 Sep 2024 to 1 Oct 2024.
12 Sep 2024 Planned initiation date changed from 22 Jul 2024 to 23 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com